Dyadic International INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Dyadic International, Inc. rebranded as Dyadic Applied BioSolutions, shifting its strategy to commercialize non-pharmaceutical proteins while reporting a wider net loss in 2025 despite new grant funding.
NASDAQ
Dyadic International's 10-K filing reveals a year of strategic shifts, including expansion into alternative proteins and continued development of its C1 platform for pharmaceutical applications, alongside financial results reflecting ongoing investments and collaborations.
NASDAQ
Dyadic International has issued stock options and restricted stock units to employees, directors, and consultants under its 2021 Equity Incentive Award Plan.